Table 3.
Demographics and clinical characteristics of COVID-19 IBD patients treated with mesalamines
| Characteristic* | 5-ASA/sulfasalazine (n=432) | No 5-ASA/sulfasalazine (n=983) | P value |
| Mean age, years (SD) | 49.3 (18.4) | 41.6 (16.7) | <0.001 |
| Female, n (%) | 204 (47.2) | 463 (47.1) | 0.96 |
| Race, n (%) | |||
| White | 367 (85) | 796 (81) | 0.16 |
| Asian | 54 (12.5) | 31 (3.2) | <0.00 |
| Black | 13 (3) | 81 (8.2) | <0.001 |
| Ethnicity, n (%) | |||
| Hispanic | 90 (20.8) | 155 (15.8) | <0.0016 |
| CD, n (%) | 99 (23) | 685 (69.7) | <0.001 |
| UC/IBD-U, n (%) | 333 (77) | 298 (30.3) | |
| Disease activity, n (%) | |||
| Remission | 231 (53.5) | 581 (59.1) | 0.34 |
| Mild | 86 (19.9) | 168 (17.1) | |
| Moderate/severe, n (%) | 99 (22.9) | 199 (20.3) | |
| Missing/unknown, n (%) | 16 (3.7) | 35 (3.5) | |
| Current smoker, n (%) | 14 (3.2) | 53 (5.4) | 0.08 |
| Any comorbidity, n (%) | 189 (43.8) | 337 (34.3) | 0.001 |
| Cardiovascular disease, n (%) | 51 (11.8) | 56 (5.7) | <0.001 |
| Diabetes, n (%) | 36 (8.3) | 46 (4.7) | 0.01 |
| Cancer, n (%) | 17 (3.9) | 16 (1.6) | 0.01 |
| Lung disease, n (%) | 50 (11.6) | 81 (8.2) | 0.046 |
| BMI ≥30 kg/m2, n (%) | 69 (16) | 166 (16.9) | 0.74 |
| Thiopurine, n (%) | 88 (20.4) | 188 (19.1) | 0.59 |
| TNF antagonist, n (%) | 75 (17.4) | 471 (47.9) | <0.001 |
| Corticosteroid, n (%) | 45 (10.4) | 65 (6.6) | 0.01 |
| Severe COVID-19, n (%) | 60 (13.9) | 51 (5.2) | <0.001 |
| Death from COVID-19 or related complications, n (%) | 27 (6.3) | 21 (2.1) | <0.001 |
*Percentages and n from each subcategory may not add up to the exact number of total reported cases due to missing values and/or non-mutually exclusive variables.
5-ASA, 5-aminosalycilates (mesalamine); BMI, body mass index; CD, Crohn’s disease; IBD-U, IBD unclassified; TNF, tumour necrosis factor.